Article info
Letters
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis
- Correspondence to Professor Markku Hakala, Division of Rheumatology, Department of Medicine, Päijät-Häme Central Hospital, Keskussairaalankatu 7, Lahti 15850, Finland; markku.hakala{at}fimnet.fi
Citation
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis
Publication history
- Accepted October 20, 2012
- First published November 12, 2012.
Online issue publication
February 05, 2013
Article Versions
- Previous version (12 November 2012).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions